62 results about "Target peptide" patented technology

The application belongs to the field of biomedical application, and more particularly relates to a cell fluorescence probe anchoring cell integrin, and a preparation method and application thereof. The cell fluorescence probe comprises a polypeptide complex, a fluorescent molecule and a cyclodextrin unit, the polypeptide complex comprises a cysteine-containing peptide, a peptide containing a bonding group and a targeting peptide which are connected in any order, the cyclodextrin unit contains a carbon-carbon double bond functional group, and is combined with the cysteine-containing peptide through a click reaction to form the polypeptide complex, the polypeptide complex is covalently connected to the fluorescent molecule through the bonding group, and the fluorescent molecule is an aggregation-induced emission compound. The double bond functional group of the modified cyclodextrin is bonded to the sulfhydryl group of the terminal cysteine of the polypeptide through a click reaction, and the sulfhydryl group of the terminal cysteine of the polypeptide is bonded to the double bond functional group of the modified cyclodextrin through a click reaction, so that the cyclodextrin is improved to protect the fluorescent molecule and prolong the fluorescent time effectiveness of the fluorescent imaging reagent.

The application relates to a fusion protein and application thereof in the field of biotechnology. A polypeptide fragment for specifically recognizing a single-molecule phospholipid membrane and a polypeptide fragment for specifically recognizing a tissue or a cell are connected to form a fusion protein which can be specifically combined to a fat body surface in a non-covalent manner, so that precise targeting of the fat body is realized. The fat body targeting peptide segment can be widely used in the fields of precise drug delivery and vaccine preparation, so as to be used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are taken as target points, and good targeting of the fat body is realized.

This invention discloses a method for preparing the multifunctional bioactive peptide Aj-UBL from sea cucumber, relating to the fields of biotechnology and biomedicine. Using the Aj-UBL coding sequence from sea cucumber as a template, the method involves PCR amplification, recombinant expression vector construction, engineered bacterial induction expression, bacterial cell disruption, affinity chromatography purification, and identification to obtain the target peptide possessing triple activities of antibacterial, antiprotozoal, and antitumor activity. This invention employs an optimized coupling process of genetic engineering and affinity chromatography to achieve high-purity, high-quality, and stable product preparation, while being environmentally friendly and free from drug resistance risks. It not only solves the problem of coordinated disease control in sea cucumber farming but also expands the high-value application of sea cucumber resources in the biomedical field, filling the technological gap in the large-scale preparation of multifunctional bioactive peptides from sea cucumber and the biological control of ciliates, possessing significant theoretical and practical application value.

The application relates to the technical field of biological medicine, and discloses a targeted ferroptosis-inducing conjugate as well as a preparation method and application thereof. The structural formula of the conjugate is as follows: the conjugate contains a prostate cancer targeting peptide segment WHDGFK, and is connected with an iron death-inducing antibacterial peptide KRIVKWIIKLLR through a disulfide bond, so that the conjugate has tumor targeting and microenvironment response release functions, not only endows the antibacterial peptide KRIVKWIIKLLR with tumor selective delivery capacity, but also realizes specific release of the active peptide in target cells by reducing the disulfide bond by using high-concentration glutathione (GSH) in tumor cells, thereby synergistically enhancing the antitumor effect and reducing the systemic toxicity.

The application discloses a method for determining key amino acid residues of bone collagen peptide promoting osteogenesis activity, belongs to the field of biological medicine and food science, and aims to solve the technical problem that traditional methods are low in efficiency, insufficient in accuracy, and cannot efficiently identify key amino acid residues of bone collagen peptide determining the activity of promoting osteogenesis. The application comprises the following steps: firstly, obtaining target bone collagen peptide and constructing a single-point alanine mutant peptide library thereof; then, sequentially performing conformation and physicochemical property characteristic analysis, binding free energy simulation calculation with specific receptor protein, and cell experiment determination of the activity of promoting osteogenesis on the target peptide and the mutant peptide; finally, screening the key amino acid residues based on multi-level joint determination of characteristic deviation, binding free energy change and activity decline ratio. The application is mainly used for quickly and accurately positioning the core functional site of bone collagen peptide promoting osteogenesis activity, and provides key theory and technical basis for efficient screening, rational design and function strengthening of osteogenic activity peptide.

The present application relates to the technical field of biological agents, and discloses a kind of M cell targeted peptide and chitosan modified dendritic mesoporous silica oral adjuvant and application thereof.The oral adjuvant includes dendritic mesoporous silica (DFNSs), and M cell targeted peptide (CKS9) modified chitosan (CS), the dendritic mesoporous silica is mixed with M cell targeted peptide modified chitosan at mass ratio 4-6:1, and is made into CKS9-CS-DFNSs oral nano adjuvant.The CKS9-CS-DFNSs oral nano adjuvant provided in the present application has good stability and safety, can effectively induce mucosal immune response and humoral immune response by oral immunization, improve the effect of oral vaccine immunization, and can be widely used in the preparation of animal inactivated vaccine, recombinant protein vaccine and polypeptide vaccine.The oral nano adjuvant preparation has low cost, simple process and is easy to mass-produce.

The present invention relates to a nucleic acid molecule encoding a chimeric polypeptide comprising a peptide of interest fused to one or more heterologous moieties, wherein at least one of the heterologous moieties is a ligand of the Sortilin receptor. The invention also relates to a chimeric polypeptide encoded by said nucleic acid molecule and uses thereof.

This application discloses a compound or a pharmaceutically acceptable salt thereof, said compound comprising a compound of formula (I) or a compound of formula (II). A radioactive element preparation comprising thereof and a radioactive element chelated therewith is also disclosed. Its use in the preparation of reagents targeting CXCR4, particularly CXCR4 tracers, more particularly in vivo CXCR4 tracers, or reagents that specifically bind to cells expressing CXCR4 is also disclosed. [Targeting Peptide-I]-Xaa1-X 1 (R 1 )L 1 -[Connector]-R x n1 (I), R x n1 -[Connector]-X 1 (R 1 )L 1 -Xaa1-[targeting peptide-II](II).

This invention provides a method for evaluating the response of rheumatoid arthritis (RA) patients to Janus kinase (JAK) inhibitor treatment. By detecting specific antibody biomarkers in a patient's biological sample and comparing the data with reference values ​​for treatment response, it is possible to predict whether a patient will respond well to the JAK inhibitor or achieve disease remission. Furthermore, this invention includes a assay kit utilizing target peptide sequences that can bind to specific antibodies and supporting materials for detection, which helps to accurately predict the therapeutic efficacy response to JAK inhibitors.

The application discloses an integrin-targeting peptide-collagenase drug combination and a drug composition constructed by the integrin-targeting peptide-collagenase drug combination. The drug combination can effectively block mechanical signals and biochemical signals mediating fibrosis, efficiently inhibit fibroblast activation, reduce the secretion of extracellular matrix proteins, and reshape the fibrotic microenvironment. Efficient reduction of fibrosis can promote the penetration of subsequent therapeutic drugs, and has a cascade penetration effect. The constructed drug composition can synergistically deliver integrin-targeting peptides and collagenase, and after release, the integrin-targeting peptides and collagenase can synergistically act in the form of free molecules in fibrotic lesions, thereby providing a new strategy for efficient delivery of fibrosis treatment drugs.

Systems and methods include techniques associated with one or more machine learning systems to predict a likelihood of binding between a target peptide and a T-cel receptor. The one or more machine learning systems may be used to generate a binding score for one or more binding amino acids of the target peptide including one or more physical or chemical properties of the binding interaction.

The application discloses a kind of recombinant fusion protein and its application in preparation anti-gastric cancer angiogenesis drug, it is related to biological medicine technical field.The amino acid sequence of the recombinant fusion protein is as shown in SEQ ID NO.1.The amino acid sequence of gastric cancer vascular targeting peptide CNTGSPYEC is recombined with the strong vascular inhibitor Endostatin gene to construct recombinant fusion protein, using the selective distribution ability of targeting peptide, can carry anti-vascular drug Endostatin more specifically enriched in gastric cancer vascular endothelial cells, to improve anti-vascular effect and antitumor effect, simultaneously because Endostatin is reduced in normal vascular and tissue distribution, can reduce corresponding toxic side effect, it has important significance to improve gastric cancer anti-vascular treatment present situation.

The application provides a microglial cell membrane camouflaged biomimetic nano preparation, a preparation method and application, and relates to the technical field of biological medicine. The microglial cell membrane camouflaged biomimetic nano preparation comprises core nanoparticles, the core nanoparticles are coated with a microglial cell membrane, and the microglial cell membrane is further modified with a functional layer. The core nanoparticles comprise a pH response carrier material and a chemotherapeutic drug; the chemotherapeutic drug is loaded in the pH response carrier material through self-assembly; the functional layer comprises a photothermal agent and a targeting peptide; and the photothermal agent and the targeting peptide are modified on the surface of the microglial cell membrane through a phospholipid coupling agent. The biomimetic nano preparation has the characteristics of double targeting (T7 targeting peptide + microglial cell homing), pH response drug release and efficient photothermal conversion, can synergistically exert photothermal-chemotherapy, significantly improves the treatment effect of GBM, and solves the problems of low drug delivery efficiency, limited single treatment effect and high toxicity in the existing GBM treatment.

Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Specifically, the targeting peptide is a component of a modified, sequence-specified adeno-associated virus (AAV) capsid protein further wherein the brain substructure may be the globus pallidus, putamen, internal capsule, caudate, claustrum, substantial nigra, motor cortex, insula,.temporal cortex, thalamus, hippocampus, subiculum, and deep cerebellar nuclei.

The present disclosure provides RNA-lipid particles and formulations comprising novel lipids and therapeutic agents, methods of making RNA-lipid particles, and methods of delivering and / or administering RNA-lipid particles. In particular, the present disclosure provides RNA-lipid particles comprising a polyomithine-based lipid conjugate or conjugate of polyomithine and a lipid-like material, and RNA (e.g., single-stranded messenger RNA encoding a peptide or protein of interest), and methods of making RNA-lipid particles. Particles comprising mRNA and polyomithine are delivered to target tissues following administration via intramuscular, intravenous, or subcutaneous routes.

Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Provided herein are viral vectors each comprising a modified capsid, wherein the modified capsid comprises at least one amino acid sequence that targets the viral vector to a distinct brain structure.

This invention relates to the field of biomedical detection technology, specifically disclosing a method for targeted detection of biomimetic nanocarriers based on GPC3 targeting peptides and macrophage membranes. The method includes: S1, acquiring the biomimetic nanocarrier and obtaining particle size distribution data; S2, obtaining nanoparticle morphology images; S3, obtaining characteristic peak signals of surface modification; S4, obtaining cell binding signals; S5, obtaining binding rate data; and S6, plotting release behavior curves. The detection process of this invention integrates multiple physical or chemical properties such as particle size, morphology, cell binding efficiency, and release characteristics. It constructs a multi-dimensional evaluation system using analytical instruments such as DLS, TEM, FTIR, UV-Vis, flow cytometry, and HPLC, overcoming the limitations of traditional detection methods that rely solely on a single indicator (such as particle size or transmission images). This multi-level, multi-angle detection approach makes the assessment of carrier performance more scientific and systematic, exhibiting higher stability and repeatability.

This invention relates to the field of granule preparation technology, and discloses a Coptis chinensis preparation for treating gastrointestinal damp-heat stagnation and its preparation method. First, the preparation components, including total alkaloids of Coptis chinensis, volatile oil of Aucklandia lappa, dry extract powder of excipient medicinal materials, chitosan, and pectin, are determined according to specific weight ratios. For different components, supercritical CO2 extraction, dynamic cyclic extraction combined with near-infrared online monitoring technology, and standardized water decoction process are used to accurately extract and prepare the preparation. Then, a chitosan-pectin nano-targeted delivery system is constructed, and colon-targeted nanoparticles are obtained by modifying colonic epithelial cell-targeting peptides. These nanoparticles are then obtained by vacuum freeze-drying and fluidized bed microsphere granulation. Simultaneously, the volatile oil of Aucklandia lappa is treated with β-cyclodextrin inclusion complex. Finally, the nanoparticles are mixed with the volatile oil inclusion complex, dry extract powder of excipient medicinal materials, enteric-coated excipients, and fillers to prepare a thermosensitive bio-ink. A thermosensitive gel framework preparation is then obtained using semi-solid extrusion 3D printing technology.

This invention belongs to the field of functional foods and bioactive peptides, specifically relating to a chicken bone collagen peptide that promotes calcium absorption, its chelate, preparation method, and application. This invention employs a rational molecular docking screening strategy, directly screening for the high-affinity peptide DFSLPQPPQ from a chicken bone collagen peptide library by simulating the interaction between peptides and calcium-sensitive receptors. This overcomes the inefficiency of traditional "blind screening" methods, achieving targeted peptide discovery based on mechanisms. The prepared peptide-calcium chelate (DFSFLPQPPQ-Ca) exhibits excellent calcium absorption-promoting performance in the Caco-2 cell model. This invention utilizes chicken bone by-products as raw materials, achieving high-value utilization of resources and providing a precise development path for poultry processing by-products based on clearly defined bioactive peptides, possessing significant industrial promotion value and economic benefits.

Disclosed are a cartilage endplate-targeting composite hydrogel, a preparation method therefor, and use thereof. The cartilage endplate-targeting composite hydrogel comprises drug-loaded exosomes modified with a cartilage-targeting peptide, calcium carbonate, chitosan, and water; the drug-loaded exosomes modified with the cartilage-targeting peptide comprise exosomes, a cartilage-targeting peptide, and salvianolic acid A. The cartilage endplate-targeting composite hydrogel is prepared by encapsulating salvianolic acid A in human mesenchymal stem cell-derived exosomes, modifying the human mesenchymal stem cell-derived exosomes with a cartilage-targeting peptide to obtain drug-loaded exosomes modified with the cartilage-targeting peptide, and then mixing the drug-loaded exosomes modified with the cartilage-targeting peptide with calcium carbonate, chitosan, and water.

This disclosure provides modified AAV vectors for expressing tripeptidyl peptidase 1 (TPP1) in objects. Some aspects of this disclosure provide modified adeno-associated virus 1 (AAV1) vectors comprising a capsid protein containing a targeting peptide and a nucleic acid molecule containing a sequence encoding a modified AAV genome, said modified AAV genome comprising a replication (rep) gene, a capsid (cap) gene, and a tripeptidyl peptidase 1 (TPP1) transgene.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

This invention belongs to the technical field of biomedicine, specifically relating to a lipid nanoparticle delivery system for in vivo CAR-T cell generation, its preparation method, and its applications. The delivery system of this invention first utilizes a high-affinity CD3ε targeting peptide to enable lipid nanoparticles (LNPs) to precisely target and efficiently transfect T cells. Secondly, it employs circular RNA (circRNA) as the CAR encoding vector; its closed circular structure resists exonuclease degradation. Finally, the aforementioned peptides and circRNA-encapsulated LNPs are integrated into a targeted delivery system using microfluidic preparation technology. The results of the embodiments demonstrate that the delivery system of this invention possesses advantages such as extremely short treatment cycles, simplified preparation processes, highly efficient targeted delivery, durable CAR expression, and high safety.

This invention relates to the field of functional food processing technology, and discloses a method for preparing and applying corn peptides that lower blood pressure. First, microwave pretreatment is used to improve the dissolution rate of corn protein. Then, dynamic temperature-controlled synergistic enzymatic hydrolysis combined with time-segmented microwave assistance is used to directionally release hydrophobic ACE-inhibiting peptides. Surface-modified magnetic materials are used to perform biomimetic affinity adsorption and magnetic separation purification of the target peptides, achieving highly selective enrichment of active ingredients. Finally, the peptides are compounded with stabilizers such as tea polyphenol-zinc chelate and Monascus purpureus extract to form a charge-matched micelle protection system. Through dynamic temperature-controlled synergistic enzymatic hydrolysis and biomimetic magnetic separation processes, efficient release and functional enhancement of active peptides are achieved, simultaneously improving ACE inhibitory activity and storage stability. The charge-matching of stabilizers and the synergistic design of components overcome the absorption barrier of active peptides. A multi-pathway regulatory system is constructed, integrating "blood pressure lowering, lipid lowering, and antioxidant" functions. Experiments have demonstrated that this application has a blood pressure lowering effect.

The invention discloses an application of a Lamp2b-IMTP fusion exosome in treatment of coronary heart disease. The specific application method comprises the following steps: preparing an exosome matrix, carrying out optimization treatment on the exosome matrix, and finally, specifically combining the optimized exosome matrix with myocardial cells through IMTP on the surface of the Lamp2b-IMTP fusion exosome in an intravenous injection administration mode. Therapeutic substances are accurately delivered to damaged myocardial tissues, which is the core advantage of the fused exosome and is also the basis of subsequent treatment effects: IMTP (myocardial targeting peptide) is modified on the surface of the exosome, and the IMTP can be accurately combined with a specific receptor on the surface of a damaged myocardial cell.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition for treating diabetic microangiopathy and a preparation method thereof, the pharmaceutical composition comprising the following raw materials in parts by weight: active drug 5-10 parts, shell copolymer 20 parts, PLGA 35-50 parts, emulsifier 1.5 parts and freeze-drying protective agent 4 parts. The shell copolymer prepared and synthesized from PCL, PEG and a targeting peptide has functions such as drug loading, self-assembly, responsiveness and targeting, the responsiveness of which depends on a disulfide bond connecting the PCL and the PEG, the disulfide bond is broken in an abnormal blood flow environment of a vascular lesion, various drugs in the nanoparticle core are released, and the drug delivery efficiency and the treatment effect are greatly improved.

The present invention relates to methods and compositions for delivering immunotherapeutics across the blood brain barrier for the treatment of brain cancer. The present application relates to sequences that enhance penetration of immunotherapeutics across the blood brain barrier (BBB), compositions comprising the sequences, and methods thereof for treating brain cancers such as glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified as enhancing penetration across the BBB when inserted into the capsid of an adeno-associated virus (AAV).

The present application relates to a kind of agglutinin joint targeting peptide modified nanosphere and its preparation method and application, belong to the biomedicine technical field.To solve the problem that the existing drug delivery system is difficult to have the integration of nasal brain barrier breakthrough, nasal long-term retention, brain lesion targeting, broad-spectrum drug loading and high biological stability, the present application provides a kind of agglutinin joint targeting peptide modified nanosphere, including polymer matrix core, biomimetic cell membrane shell and double-ligand functionalization surface crown layer in turn from inside to outside.The nanosphere of the present application can prolong the nasal retention time and efficiently penetrate the nasal mucosa barrier by relying on the synergistic effect of core-shell-crown three-layer structure, realize transnasal brain and lesion precise targeting, improve drug delivery efficiency and efficacy, and reduce toxic side effects.The nanosphere of the present application has a wide range of drug loading spectrum, suitable for the drug demand of various central nervous system diseases, and has excellent clinical transformation value and application prospect.

The present invention relates to the field of peptide drugs, and particularly to a triple-target peptide and a derivative thereof. The triple-target peptide provided by the present invention exerts effects of lowering blood glucose, reducing blood lipids, and weight loss. Based on the above studies, the triple-target peptide provided by the present invention is further long-acting modified, and while retaining excellent effects for the specific indications described above, also has long-acting advantages, which can reduce dosing frequency, improve medication convenience, and enhance patient compliance. Experimental results show that the peptide and the long-acting derivative thereof provided by the present invention can significantly lower blood glucose, reduce blood lipids and / or induce weight loss, and can effectively prevent, treat, or ameliorate diabetes, obesity, obesity-related diseases, or metabolic disorders.

The application discloses a peptide targeting a PARP1 protein, a peptide PROTC and application thereof, and belongs to the technical field of biological medicines, wherein the amino acid sequence of the peptide targeting the PARP1 protein is fdklGsGsG, and the targeting peptide of the application is helpful to realize targeted treatment of tumors.